Fig. 3.

Relationship between neutrophil-to-lymphocyte ratio (NLR) and progression-free survival (PFS). a Median PFS of patients with an NLR of < 3 before treatment was 3.4 months, whereas that of patients with an NLR of ≥ 3 was 2.9 months (p = 0.484). b Median PFS of patients with an NLR of < 3 at 2 weeks after the initial treatment was 5.3 months, whereas that of patients with an NLR of ≥ 3 was 2.1 months (p = 0.00528). c Median PFS of patients with an NLR of < 3 at 4 weeks after the initial treatment was 5.3 months, whereas that of patients with an NLR of ≥ 3 was 2.0 months (p = 0.00515)